Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
Person
|
| gptkbp:affiliation |
gptkb:Amgen
|
| gptkbp:awards |
gptkb:National_Academy_of_Medicine_member
|
| gptkbp:collaborations |
Various academic institutions
|
| gptkbp:contribution |
Development of novel therapies
|
| gptkbp:education |
gptkb:University_of_California,_San_Diego
|
| gptkbp:field |
Biotechnology
|
| gptkbp:has_expertise_in |
Drug development
|
| gptkbp:hasLanguage |
Conferences and seminars
|
| https://www.w3.org/2000/01/rdf-schema#label |
Dr. Roger Perlmutter
|
| gptkbp:impact |
Patient care improvements
|
| gptkbp:influence |
Biopharmaceutical industry
|
| gptkbp:innovation |
Therapeutic antibodies
|
| gptkbp:involved |
Clinical trials
|
| gptkbp:knownFor |
Research in immunology
|
| gptkbp:leadership |
Amgen's_R&D_department
|
| gptkbp:mentor |
Young scientists
|
| gptkbp:network |
Global scientific community
|
| gptkbp:occupation |
Pharmaceutical Executive
|
| gptkbp:position |
Executive Vice President
|
| gptkbp:publications |
Numerous scientific articles
|
| gptkbp:researchFocus |
Cancer immunotherapy
|
| gptkbp:vision |
Transforming medicine through science.
|